Reminder – Melanoma Consumer Breakfast this Saturday 6th October 2108

Sat 6th October 2018, 8:00-9:30am All members of the melanoma community are invited to attend a Melanoma Consumer Breakfast. The Breakfast is part of the Australasian Melanoma Conference – which also has great consumer forums. The program is on the website. All bookings can be made via the conference website

Melanoma survivors march to honour lost friends and raise awareness

Melanoma has a reputation for being one of the most curable types of cancers, but that does not mean much to survivors such as Jay Allen and Aaron Kelly.

Free skin checks for South West community

The Bunbury Skin Cancer Clinic is partnering with melanomaWA to provide the community with free skin checks on February 24.

Townsville’s First Ever Twilight Melanoma March

She will next month join Townsville’s first ever twilight Melanoma March in honour of her mother, Gina Sellen, who lost her battle against the deadly cancer in 2016.

Cancer in the News

Feature Articles

UV, Sex, and Age Contribute to Melanoma Tumor Evolution

Although ultraviolet (UV) radiation damage and clock-like mutations associated with cell division contribute to melanoma risk, sex, and age may represent the final mutational composition of skin cancer, according to study research published in the British Journal of Dermatology.


Posted in Melanoma News, Health Professionals, Of Interest

Melanoma Advances Improved OS in Patients With Brain Mets

Advances that emerged from 2007 – 2016 in the treatment of melanoma, including targeted agents, immunotherapy, and new radiotherapy techniques, led to significant improvement in overall survival for patients with melanoma and brain metastases, according to findings from a large population-based cohort study.


Posted in Melanoma News, Health Professionals, Of Interest

Dr. Chandra on the Incidence of Targetable Mutations in Melanoma

Sunandana Chandra, MD, MS, assistant professor of medicine, Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine, discusses the incidence of targetable mutations in melanoma.


Posted in Melanoma News, Health Professionals, Video Reports

Investigators Present Updated Results of the OpACIN Trial for Melanoma

Christian U. Blank, MD, PhD, medical oncologist in the Division of Immunology at the Netherlands Cancer Institute, discusses the most recent data from the phase 1b OpACIN trial (NCT02437279) of ipilimumab (Yervoy) and nivolumab (Opdivo) in patients with macroscopic stage III melanoma.


Posted in Melanoma News, Health Professionals, Clinical Trials